Advanced Enzyme Technologies Share Price: ABS Law Ka Tension Badha, ₹68 Lakh Ki Payout Ne Machaya Shor!

ENVIRONMENT
Whalesbook Logo
AuthorAarav Shah|Published at:
Advanced Enzyme Technologies Share Price: ABS Law Ka Tension Badha, ₹68 Lakh Ki Payout Ne Machaya Shor!
Overview

Arre yaar, Advanced Enzyme Technologies Ltd ne India ke Access and Benefit Sharing (ABS) law ke chakkar mein ek Indian village ko **₹68 lakh** de diye hain! Isse biotech companies par regulatory pressure badh gaya hai, aur R&D par bhi asar pad sakta hai.

Yeh Payout Achanak Kyun?

Basically, Advanced Enzyme Technologies (ADVENZYMES) ne Maharashtra ke Dapur village ko yeh badi amount di hai. Yeh sab India ke Biological Diversity Act, 2002 ke ABS framework ke under hua hai. Company pehle se hi biological resources use karti aa rahi hai product banane ke liye, par ab is rule ki wajah se operational costs aur regulatory risks badh gaye hain. Yeh sab cheezein R&D planning ko complicated bana rahi hain. Company ka stock abhi lagbhag ₹290 par trade kar raha hai, market cap ₹3,200 crore ke aas paas hai, aur P/E ratio 20s mein hai. Analyst log bhi confuse hain, kuch 'Strong Buy' bol rahe hain toh kuch 'Sell'.

ABS Rules Ka Game Aur Confusion

Yeh ABS mechanism international Nagoya Protocol se judaa hua hai, jisme companies ko genetic resources se hone wale benefits local communities ke saath share karne padte hain. Pehle bhi kuch aise cases hue hain, par rules lagatar change ho rahe hain. Haal hi mein India ke Biodiversity Act mein kuch changes hue hain taaki compliance aasan ho aur innovation badhe, jaise ki cultivated crops ke liye exemptions. Lekin phir bhi, alag-alag states ke ABS rules aur legal uncertainty ki wajah se companyon ke liye kaam karna mushkil ho raha hai. Kai companies ko toh yeh ABS obligations ke baare mein pata bhi nahi hai.

Sell Rating Ke Peeche Kya Hai?

Jabki zyadaatar analysts positive hain, MarketsMOJO ne November 21, 2025 ko 'Sell' rating di hai. Unki bearish technical grade aur revise hua Mojo Score kuch underlying problems bata rahe hain. Yeh jo ABS payment hui hai, isse sirf direct costs hi nahi badhengi, balki future mein aur bhi claims, litigation, ya R&D delays ka risk ho raha hai. Cultivated sources par shift hone ke liye farming aur supply chains mein bhi heavy investment chahiye, jiska impact abhi valuation mein shayad dikh nahi raha. Company ki 5 saal ki sales growth 7.48% rahi hai aur 3 saal ka return on equity (ROE) sirf 10.1% hai, jo earning growth par sawaal utha rahe hain. Iss 'Strong Buy' aur 'Sell' ratings ke difference se pata chalta hai ki company ke future aur biodiversity rules ke adapt karne ki asli cost ko lekar sabke views alag hain.

Aage Kya Hoga?

Advanced Enzyme Technologies ko future mein biodiversity compliance ko apne strategy mein integrate karna hoga. Company ka R&D focus aur product portfolio kaafi strong hai. ABS rules ke saath proactive rehna, jaise ki cultivated sources develop karna aur benefit sharing ko clear rakhna, bahut important hoga. Agar company is situation ko positive mein badal payi, toh yeh cost ek competitive edge ban sakti hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.